

NIH funding opportunities

18 Jan 2024 (#01)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[Stavros Niarchos Foundation \(SNF\) Global Center for Child and Adolescent Mental Health, Child Mind Institute and Global Health Initiative \(GHI\) SNF Global Center Researchers Fellowship program](#). The SNF Global Researchers Fellowships are awards equivalent to a total of up to USD \$600,000 over the 4–5 year duration of the program. They target exceptionally creative, early-career scientists in low- and middle-income countries (LMIC) with records of conducting high-impact, innovative projects in their region and local communities that demonstrate the potential to revolutionize the field of child and adolescent mental health. Eligible institutions will nominate up to two candidates for the worldwide competition. We anticipate the first call for applications to occur in March 2024.

[NOT-AG-23-077 NIA Intervention Testing Program \(ITP\) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice](#). The National Institute on Aging (NIA) Interventions Testing Program (ITP) was established to test compounds purported to extend lifespan and/or delay the onset of disease and disability. The NIA ITP tests such compounds in genetically heterogeneous mice, first using lifespan to assess the efficacy of interventions. There are three sites that perform the testing, one at the University of Michigan, one at the University of Texas Health Sciences Center-San Antonio, and one at The Jackson Laboratory. The deadline for receipt of proposals is February 28, 2024.

[NOT-OD-24-037 Inviting Comments on the National Institutes of Health \(NIH\) Strategic Plan for Data Science 2023-2028](#). The purpose of this Request for Information (RFI) is to solicit public comments on the updated NIH Strategic Plan for Data Science, 2023-2028. The NIH is publishing this Notice to solicit input on topics under consideration for the strategic plan from its stakeholders, including members of the scientific community, academic institutions, the private sector, health professionals, professional societies, advocacy groups, and patient communities, as well as other interested members of the public. Responses must be received by 11:59:59 pm (ET) on March 15, 2024.

[NOT-OD-24-045 Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Sites for the Environmental influences on Child Health Outcomes \(ECHO\) IDeA States Pediatric Clinical Trials Network- 3 \(UG1 Clinical Trial Required\)](#). The Environmental influences on Child Health Outcomes (ECHO) Program Office intends to

publish a Notice of Funding Opportunity (NOFO) inviting applications from entities/institutions in Institutional Development Award (IDeA)-eligible States to participate as Clinical Sites in the Environmental influences on Child Health Outcomes IDeA States Pediatric Clinical Trials Network (ECHO ISPCTN). This NOFO runs in parallel with companion notice of intent to publish NOFO that will solicit applications for a Data Coordinating and Operations Center (DCOC) within the IDeA States. A sum of \$7,000,000 has been set aside for the FY 2025. 15-20 awards in FY 2025.

Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates
*Expiration Date: May 8, 2023. **Modified Expiration Date: May 8, 2024***

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

1. **[NOT-GM-24-001](#) Availability of Administrative Supplements to IDeA Awards to Fund Team Science Development Projects.** The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for administrative supplements to current recipients of the Institutional Development Award (IDeA) program including Centers of Biomedical Research Excellence (COBRE) (P20, P30), IDeA Networks of Biomedical Research Excellence (INBRE) (P20), and IDeA Networks for Clinical and Translational Research (IDeA-CTR) (U54) awards. Application Due Date March 1, 2024, by 5:00 PM local time of the applicant organization.

2. **[NOT-HG-24-012](#) Advancing Genomic Technology Development for Research and Clinical Application.** The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics. Successful applicants are expected to work with the [NHGRI Technology Development Coordinating Center](#) to accelerate technology development and progress in the field of genomics. This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 10, 2027.

3. **[NOT-MH-24-130](#) Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia.** NIMH is issuing this Notice of Special Interest (NOSI) to encourage research on task-based behavioral measures that engage brain systems relevant to anhedonia. These behavioral measures are expected to be used as a proxy for brain target engagement, therefore neuroimaging or other brain measures with similar spatial resolution should be used to demonstrate that the proposed behavioral tasks engage brain systems relevant to anhedonia. The goal is to identify a battery of behavioral tasks that can be used as quantitative tools for future use in the evaluation of dysfunction within domains of mental health relevant to anhedonia and for future treatment development. This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through January 8, 2027.

4. **[NOT-DC-24-001](#) National Institute on Deafness and Other Communication Disorders (NIDCD) is Interested in Supporting Research on the Impact of Post-Acute Sequelae of SARS-CoV-2 Infection on Mission Specific Sensory and Communication Disorders.** Post-acute sequelae of SARS-CoV-2 (PASC), also referred to as long COVID, is defined as signs, symptoms, and conditions that continue or develop after initial COVID-19 infection. Such signs, symptoms, and conditions linger or develop 4 or more weeks following the acute infection, and can last weeks, months, and even years. Furthermore, PASC-related symptoms are wide ranging, and can have cardiopulmonary, gastrointestinal, dermatologic, endocrine, psychiatric and/or neurological manifestations, including sensory dysfunction and cognitive-communication difficulties. Further research is critical to understand the symptomatology, pathogenesis, and

underlying mechanisms of PASC. NIDCD invites applications for research on PASC in relation to NIDCD's scientific programs of hearing, balance, taste, smell, voice, speech and language. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond *in vitro* and animal models. This notice applies to due dates on or after January 30, 2024 and subsequent receipt dates through January 30, 2027.

5. **[NOT-EB-23-022 Quantum Sensing Technologies in Biomedical Applications](#)**. The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of General Medical Sciences (NIGMS), National Center for Advancing Translational Sciences (NCATS), and National Cancer Institute (NCI) are soliciting applications proposing to advance research on quantum sensing directed toward biomedical applications. This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through January 27, 2027.

6. **[NOT-OD-24-038 Health Influences of Gender as a Social and Structural Variable](#)**. The NIH Office of Research on Women's Health (ORWH) and our Institute, Center, and Office (ICO) partners are issuing this Notice to highlight interest in receiving research and training grant applications focused on health impacts of [gender-related social and structural variables](#). For this Notice, relevant domains of gender are gender roles and norms, gender relations, gender equity/inequity, gender equality/inequality, gender-related power dynamics, and structural sexism. Applications can consider one or more domains as they relate to health. This NOSI applies to due dates on or after January 25, 2024, and subsequent receipt dates through September 30, 2025.

Notice of Funding Opportunity (NOFO)

1. **[RFA-CA-24-018 Advanced Development of Informatics Technologies for Cancer Research and Management \(U24 Clinical Trial Optional\)](#)**. The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's [Informatics Technology for Cancer Research \(ITCR\)](#) Program, this NOFO focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion NOFOs listed above.

Due dates: June 11, 2024; November 15, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date. **Budget:** NCI intends to fund an estimate of 4 awards, corresponding to a total of \$3.6M, for fiscal year 2025. Budgets are limited to \$600,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is five years.

2. **[RFA-CA-24-019 Sustained Support for Informatics Technologies for Cancer Research and Management \(U24 Clinical Trial Optional\)](#)**. The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research ([ITCR](#)) Program, this NOFO focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR NOFOs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the

resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

Due dates: June 11, 2024; November 15, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date. **Budget:** NCI intends to fund an estimate of 1 award, corresponding to a total of \$1,130,000, for fiscal year 2025. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

3. [RFA-AI-23-065](#) Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed). The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications from single institutions or a consortium of institutions to participate in the Centers for Excellence in Translational Research (CETR) program. This program will support multidisciplinary translational research Centers focused on generating, validating, and advancing medical countermeasures against bacteria or fungi listed in the NOFO with known and emerging resistance to current therapies.

Due dates: April 29, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIAID intends to commit \$25 million in FY 2025 to fund 3-4 awards. Application budgets are not expected to exceed \$5 million in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. [PAR-23-318](#) Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional). The purpose of this Notice of Funding Opportunity (NOFO) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, and/or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. All applicants must address both the R21 and R33 phases.

Due dates: March 22, 2024, March 21, 2025, March 20, 2026. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The R21 phase may not exceed \$125,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed \$200,000 in direct costs in any single year of the R33 phase. The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

5. [RFA-MH-25-140](#) Streamlining mental health interventions for youth living with HIV in Low- and Middle-Income Countries (R01 Clinical Trial Optional). There is a practical need to develop streamlined versions of mental health interventions for youth living with HIV (YLWH) that can be feasibly implemented and scaled up in low- and middle-income countries (LMICs). The purpose of this initiative is to use novel methods to streamline evidence-based mental health interventions for YLWH so that they require fewer resources to deliver while still leading to clinically meaningful improvements in mental health and HIV outcomes.

Due dates: August 12, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: NIMH intends to commit \$2,500,000 in total costs in FY 2025 to fund 2-4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. [PAR-23-301](#) Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed). The goal of this NOFO is to support applications for novel theory and

methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.

Due dates: February 16, 2024 through to October 16, 2026. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

7. [PAR-23-318](#) Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional). The purpose of this NOFO is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, and/or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. All applicants must address both the R21 and R33 phases.

Due dates: March 22, 2024, March 21, 2025, March 20, 2026. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: The R21 phase may not exceed \$125,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed \$200,000 in direct costs in any single year of the R33 phase. The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

8. [RFA-DA-25-009](#) Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed). The NOFO aims to support studies to expand our knowledge of mechanisms driving autophagy and to identify autophagy pathways that can be exploited to control HIV infection and pathogenesis of comorbidities in the context of addictive substance use. The NOFO invites mechanistic studies and preclinical studies testing effects of compounds known to interfere with autophagy pathways on HIV infection and immune system. All studies must clearly address the intersection between HIV and substance use.

Due dates: November 14, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: NIDA intends to support up to four awards for RFA-DA-25-009 and [RFA-DA-25-010](#), corresponding to a total of \$2,000,000 in FY 2025. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

9. [RFA-DA-25-023](#) Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed). This notice of funding opportunity (NOFO) aims to support research programs that adopt innovative scalable technologies to inventory, register and molecularly profile distributed cell ensembles encoding the effects of addictive substances, across various stages of exposure (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches capable of integrating data generated through population-scale measurements of cellular activity dynamics in behaving rodents, with other granular data modalities, collected from the same cells at single-cell resolution, such as transcriptomic class, epigenetic state, connectivity and spatial localization. The overarching goal is to inform new models for the mechanisms whereby cells are recruited into neuronal ensembles to encode addiction-associated neurobehavioral states.

Due dates: February 21, 2024, February 20, 2025, February 23, 2026. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIDA intends to commit \$2M in FY2024 to fund 1-3 awards. Applications may not request more than \$700,000 direct costs for any one year. The maximum project period is 5 years.

10. [RFA-FD-24-013](#) Implementation of U.S. Food Safety Modernization Act - Identifying, Researching and Implementing Alternative Methods to Expand the Reach Across the Global Supply Chain (U01) - Clinical Trials Not Allowed. This Cooperative Agreement represents the continuation and further expansion of well-established collaborations between the Inter-American Institute for Cooperation on Agriculture (IICA) and the Food and Drug Administration (FDA), in support of data-driven and science-based public health strategies and approaches that align well with FDA domestic and global goals. The purpose of this cooperative agreement is to support research and needs assessments to identify, develop and implement alternative approaches and methods to current training modalities in support of the Food Safety Modernization Act (FSMA) Rules and the New Era of Smarter Food Safety Blueprint.

Due dates: February 19, 2024 or [Standard dates](#) apply. All applications are by 11:59 PM Eastern Time on the application due date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for FOUR (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA /OGPS intends to commit up to \$500,000 in FY {2024} to fund {ONE} award.

11. [RFA-FD-24-014](#) Strengthening Regulatory Systems to Improve Global Food and Medical Product Quality and Safety (U01) Clinical Trials Not Allowed. This Cooperative Agreement represents the continuation and further expansion of well-established collaborations between the World Health Organization (WHO) and the Food and Drug Administration (FDA), in support of data-driven and science-based public health strategies and approaches that align well with FDA domestic and global goals. This cooperative agreement is expected to contribute to the knowledge base of the current food and medical products safety globally and address specific challenges in the global efforts to ensure safety of such products. Relevant strategies include: 1) developing global norms and standards; 2) articulating evidence-based policy options, including those relating to regulatory systems performance; and 3) providing technical support to national regulatory authorities and governments through systems strengthening efforts.

Due dates: February 19, 2024 or [Standard dates](#) apply. All applications are by 11:59 PM Eastern Time on the application due date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for FOUR (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA /OGPS intends to commit up to \$750,000 in FY {2024} to fund {ONE} award. It is anticipated that up to 1 (one) award will be made, not to exceed \$750,000 in total costs (direct plus indirect), per award.

12. [RFA-FD-24-024](#) Natural History, Clinical Outcome Assessment, and Biomarker Studies of Rare Neurodegenerative Diseases (U01) Clinical Trials Optional. The purpose of this funding opportunity is to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. Through the support of studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.

Due date: May 6, 2024, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for three (3) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA/OOPD intends to fund approximately \$2,000,000 for FY 2024 in support of this grant program. It is anticipated that 2 to 3 awards will be made.

13. [RFA-MH-25-140](#) Streamlining mental health interventions for youth living with HIV in Low- and Middle-Income Countries (R01 Clinical Trial Optional). There is a practical need to develop streamlined versions of mental health interventions for youth living with HIV (YLWH) that can be feasibly implemented and scaled up in low- and middle-income countries (LMICs). The purpose of this initiative is to use novel methods to streamline evidence-based mental health interventions for YLWH so that they require fewer resources to deliver while still leading to clinically meaningful improvements in mental health and HIV outcomes.

Due date: August 12, 2024 All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Letter of Intent: 30 days prior to the application due date.

Budget: NIMH intends to commit \$2,500,000 in total costs in FY 2025 to fund 2-4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Faculty of Medicine and Health Sciences Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO) 009 Kth Floor, Teaching Block, Tygerberg Campus.	Stellenbosch Campus Division for Research Development (DRD) 2041 Krotoa Building, Ryneveld Street
Enquiries: cdevries@sun.ac.za / fmhsgmo@sun.ac.za	Enquiries: research@sun.ac.za
Add "Interest in NIH opportunity" in the subject line. Add the <i>notice number</i> in the text of the email.	